» Articles » PMID: 34388527

Pharmacological Basis and New Insights of Taxifolin: A Comprehensive Review

Overview
Date 2021 Aug 13
PMID 34388527
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

The pharmacological characteristics of phytochemicals have prompted a lot of interest in their application in disease management. Due to the high incidence of cancer related mortality and morbidity throughout the world; experiments have concentrated on identifying the anticancer potential of natural substances. Many phytochemicals such as flavonoids and their derivatives produced from food offer a variety of new anti-cancer agents which prevent the cancer progression. Taxifolin, a unique bioactive flavonoid, is a dietary component that has grabbed the interest of dietitians and medicinal chemists due to its wide range of health benefits. It is a powerful antioxidant with a well-documented effect in the prevention of several malignancies in humans. Taxifolin has shown promising inhibitory activity against inflammation, malignancies, microbial infection, oxidative stress, cardiovascular disease, and liver disease. Anti-cancer activity has been shown to be relatively significant than other activities investigated in vitro and in vivo with a little or no side effects to the normal healthy cells. In summary this review offers the synopsis of recent breakthroughs in the use of taxifolin as a cancer treatment, as well as mechanisms of action. However, to develop a medicine for human usage, more study on pharmacokinetic profile, profound molecular mechanisms, and drug safety criteria should be conducted utilizing well-designed randomized clinical trials.

Citing Articles

Bioactivity Assessment of Functionalized TiO Powder with Dihydroquercetin.

Niksic V, Pirkovic A, Spremo-Potparevic B, Zivkovic L, Topalovic D, Nedeljkovic J Int J Mol Sci. 2025; 26(4).

PMID: 40003940 PMC: 11855565. DOI: 10.3390/ijms26041475.


Natural Compounds and Histone Deacetylase Inhibitors: A Combined Approach Against mCRPC Cells.

Alimudin J, Betts Z, Deveci Ozkan A Biomedicines. 2025; 13(2).

PMID: 40002709 PMC: 11853668. DOI: 10.3390/biomedicines13020296.


Taxifolin regulates SLC31A1-mediated cuproptosis and tumor progression in hepatocellular carcinoma.

Li J, Wang Y, Bao L, Chen G, Ye Q, He C Hum Cell. 2025; 38(2):37.

PMID: 39752031 DOI: 10.1007/s13577-024-01168-6.


Effect of Dihydroquercetin During Long-Last Growth of Yeast: Anti-Aging Potential and Hormetic Properties.

Pusev M, Klein O, Gessler N, Bachurina G, Filippovich S, Isakova E Int J Mol Sci. 2024; 25(23).

PMID: 39684285 PMC: 11641753. DOI: 10.3390/ijms252312574.


Unraveling the chemotherapeutic potential of taxifolin ruthenium-p-cymene complex in breast carcinoma: Insights into AhR signaling pathway in vitro and in vivo.

Das A, Bhattacharya B, Gayen S, Roy S Transl Oncol. 2024; 49:102107.

PMID: 39181115 PMC: 11388270. DOI: 10.1016/j.tranon.2024.102107.